The Technical Analyst
Merus NV [MRUS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Merus NV Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
2.82% $41.97
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 429.15 mill |
| EPS: | -3.00 |
| P/E: | -13.99 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 57.88 mill |
| Avg Daily Volume: | 0.577 mill |
| RATING 2024-04-24 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -13.99 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.38x |
| Company: PE -13.99 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-14.23 (-133.91%) $-56.20 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 40.18 - 43.76 ( +/- 4.27%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-19 | Shuman Harry | Sell | 115 | Common Shares |
| 2023-12-15 | Silverman Peter B. | Buy | 1 286 | Common Shares |
| 2023-12-15 | Silverman Peter B. | Buy | 21 100 | Common Shares |
| 2023-12-15 | Silverman Peter B. | Sell | 21 100 | Share Option (right to buy) |
| 2023-12-15 | Silverman Peter B. | Sell | 22 386 | Common Shares |
| INSIDER POWER |
|---|
| 69.35 |
| Last 99 transactions |
| Buy: 2 523 001 | Sell: 3 636 553 |
Forecast:
16:00 - $42.01
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $42.01
Forecast 2: 16:00 - $42.01
Forecast 3: 16:00 - $42.01
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $41.97 (2.82% ) |
| Volume | 0.738 mill |
| Avg. Vol. | 0.577 mill |
| % of Avg. Vol | 127.89 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MRUS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | buy | $40.33 | N/A | Active |
|---|
MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Latest Press Releases
2024-04-24 10:00:00 - Press Release
Merus Announces Abstracts Accepted For Presentation At The 2024 Asco Annual Meeting
Petosemtamab in combination with pembrolizumab in 1l hnscc initial interim clinical data selected for rapid oral session presentation
2024-04-08 12:00:00 - Press Release
Merus Presents Preclinical Data Demonstrating Efficacy Of Zeno In Cancer Models With High Nrg1 Expression At The Aacr Annual Meeting 2024
Utrecht, the netherlands and cambridge, mass., april 08, 2024 (globe newswire) -- merus n.v. (nasdaq: mrus) (“merus”, “the company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (biclonics® and triclonics®), today announced preclinical data on zenocutuzumab (zeno) in cancer models with high neuregulin 1 (nrg1) expression were presented at the american association of cancer research (aacr) annual meeting 2024.
2024-03-06 08:00:00 - Press Release
Gilead And Merus Announce Collaboration To Discover Novel Antibody-based Trispecific T-cell Engagers
Foster city, calif.--(business wire)--gilead sciences, inc. (nasdaq:gild) and merus n.v. (nasdaq:mrus) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (taa) targeting trispecific antibodies. gilead and merus agreed to collaborate on the use of merus' proprietary triclonics® platform along with gilead's oncology expertise to research and develop multiple, separate preclinical research programs. merus is a clinical-stage onco.
2024-02-28 16:15:00 - Press Release
Merus Announces Financial Results For The Fourth Quarter And Full Year 2023 And Provides Business Update
- petosemtamab in 1l hnscc in combination with pembrolizumab initial interim clinical data planned for 2q24; preparing for a potential phase 3 trial
2024-01-31 08:00:00 - Press Release
Merus To Participate In Upcoming Investor Conferences
Utrecht, the netherlands and cambridge, mass., jan. 31, 2024 (globe newswire) -- merus n.v. (nasdaq: mrus), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (biclonics® and triclonics®), today announced that bill lundberg, m.d., president, chief executive officer of merus, will participate in a fireside chat at the following investor conferences:
Latest News
2024-04-03 13:47:03 - CNBC Television
Under-the-radar biotech bets
Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.
2024-02-20 11:06:56 - Zacks Investment Research
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-01-31 08:00:00 - GlobeNewsWire
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences:
2024-01-09 06:46:08 - Zacks Investment Research
Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?
Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2023-12-28 11:16:13 - Zacks Investment Research
Wall Street Analysts See a 52.96% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 53% in Merus N.V. (MRUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-12-18 20:57:13 - Seeking Alpha
Merus: (Maybe) Building A Better Bispecific
Merus N.V. is a biotech company developing novel bispecific antibodies, with two drugs in development for unmet needs in head and neck cancer and solid tumors. Petosemtamab, targeting EGFR and LGR5, showed promising results in a phase 1/2 trial for head and neck cancer, with an objective response rate of 35.7%. Zenocutuzumab, targeting HER2/HER3 in NRG1-positive NSCLC and pancreatic cancer, demonstrated an overall response rate of 37.2% and 42.4%.
2023-12-05 13:32:34 - Zacks Investment Research
Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade
Merus N.V. (MRUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-11-01 08:00:00 - GlobeNewsWire
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:
2023-10-17 06:01:04 - Zacks Investment Research
Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?
Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2023-10-15 19:58:00 - GlobeNewsWire
Merus Announces Business Update Conference Call
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that it will host a conference call to discuss a business update on Monday, October 16, 2023 at 7:30 a.m. ET.